New concepts about graft-versus-host and graft-versus-leukaemia-reactions. A summary of the 5th International Symposium held in Munich, 21 and 22 March 2002

Bone Marrow Transplantation

Volumn 30, Issue 9, 2002, Pages 549-556

  Munker, R ^a   Gunther W ^b   Kolb, H J ^b  

^a Louisiana State University School of Medicine Shreveport   (United States)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Gene therapy; Graft versus host reactions; Graft versus leukaemia reactions; Immunotherapy

Indexed keywords

ALLOANTIGEN; ANTINEOPLASTIC AGENT; CARMUSTINE; CORTICOSTEROID; CYTOKINE; FLUDARABINE; HISTOCOMPATIBILITY ANTIGEN; IMMUNOSUPPRESSIVE AGENT; MELPHALAN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; CELL DIFFERENTIATION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA POLYMORPHISM; EXPERIENCE; GENE INSERTION; GENE MUTATION; GENE THERAPY; GENE TRANSFER; GERMANY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOPOIESIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MEDICAL RESEARCH; MESENCHYME CELL; MOUSE; NONHUMAN; PERIPHERAL BLOOD STEM CELL; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; RISK FACTOR; STROMA CELL; SYMPOSIUM; TUMOR REGRESSION; UNIVERSITY HOSPITAL; ANIMAL; CYTOLOGY; HEMATOPOIETIC STEM CELL; HISTOCOMPATIBILITY; METABOLISM;

ANIMALS; GENE THERAPY; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; TRANSPLANTATION IMMUNOLOGY;

EID: 0036857694     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703690     Document Type: Conference Paper

References (23)

1. Rossig C, Bollard CM, Nuchtern JG et al. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T cell receptors: potential for improved immunotherapy. Blood 2002; 99: 2009-2016.
2. Horwitz EM, Prockop DJ, Gordon PL et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 2001; 97: 1227-1231.
3. Li Z, Düllmann J, Schiedlmeier B et al. Murine leukemia induced by retroviral gene marking. Science 2002; 296: 497.
4. Oostendorp RA, Harvey KN, Kusadasi N et al. Stromal cell lines from mouse aorto-gonads-mesonephros subregions are potent supporters of hematopoietic stem cell activity. Blood 2002; 99: 1183-1189.
5. Feuring-Buske M, Frankel AE, Alexander RL et al. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Res 2002; 62: 1730-1736.
6. - progenitor cells from patients with acute myeloid leukemia. Blood 2002; 97: 3882-3889.
7. Buske C, Feuring-Buske M, Abramovich C et al. Deregulated expression of HOXB4 enhances the primitive growth activity of human hematopoietic cells. Blood 2002; 100: 862-868.
8. Smith ES, Mandokhot A, Evans EE et al. Lethality based selection of recombinant genes in mammalian cells: application to identifying tumour antigens. Nat Med 2001; 7: 967-972.
9. Bachar-Lustig E, Li HW, Gur H et al. Induction of donor-type chimerism and transplantation tolerance across major histocompatibility barriers in sublethally irradiated mice by Sca-1 (+) Lin (-) bone marrow progenitor cells: synergism with non-alloreactive (host x donor) F (1) T cells. Blood 1999; 94: 3212-3221.
10. Gur H, Krauthgamer R, Berrebi A et al. Tolerance induction by megadose hematopoietic progenitor cells: expansion of veto cells by short term expansion of purified human CD34 cells. Blood 2002; 99: 4174-4181.
11. Reich-Zeliger S, Zhao Y, Krauthgamer R et al. Anti-third party CD8 CTLs as potent veto cells: coexpression of CD8 and FasL is a prerequisite. Immunity 2000; 13: 507-515.
12. Kurokawa T, Oelke M, Mackensen A. Induction and clonal expansion of tumor specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells. Int J Cancer 2001; 91: 749-756.
13. Dickinson AM, Cavet J, Cullup H et al. GVHD risk assessment in hematopoietic stem cell transplantation: role of cytokine gene polymorphisms and an in vitro human skin explant model. Hum Immunol 2001: 62; 1266-1276.
14. Teshima T, Ordemann R, Reddy P et al. Acute graft-versus host disease does not require alloantigen expression on host epithelium. Nat Med 2002; 8: 575-581.
15. Wendtner CM, Kofler DM, Theiss HD et al. Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors. Blood 2002; 100: 1655-1661.
16. Mavroudis DA, Dermine S, Molldrem J et al. Specific depletion of alloreactive T cells in graft-versus-host and graft-versus-leukaemia reactions. Br J Haematol 1998; 101: 565-570.
17. Cavazzana-Calvo M, Andre-Schmutz I, Hacein-Bey-Abina S et al. Improving immune reconstitution while preventing graft-versus-host disease in allogeneic stem cell transplantation. Semin Hematol 2002; 39: 32-40.
18. Stanislawski T, Voss RH, Lotz C et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2001; 2: 962-970.
19. + hematopoietic stem cells. Blood 2002; 99: 2037-2044.
20. Dolstra H, Fredrix H, Maas F et al. A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J Exp Med 1999; 189: 301-308.
21. Clark RE, Dodi IA, Hill SC et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 2001; 98: 2887-2893.
22. Norbury LC, Clark RE, Christmas SE. b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia. Br J Haematol 2000; 109: 616-621.
23. Dickinson AM, Wang XN, Sviland L et al. In situ disection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med 2002; 8: 410-414.